Dr. Martens (LON:DOCS) Insider Purchases £149.12 in Stock

Dr. Martens plc (LON:DOCS – Get Free Report) insider Ije Nwokori acquired 233 shares of the business’s stock in a transaction that occurred on Wednesday, May 13th. The shares were bought at an average price of GBX 64 per share, with a total value of £149.12.

Ije Nwokori also recently made the following trade(s):

Get Dr. Martens alerts:

• On Wednesday, April 15th, Ije Nwokori sold 204,051 shares of Dr. Martens stock. The stock was sold at an average price of GBX 66, for a total transaction of £134,673.66.
• On Tuesday, April 14th, Ije Nwokori purchased 232 shares of Dr. Martens stock. The shares were purchased at an average cost of GBX 65 per share, for a total transaction of £150.80.

Dr. Martens Price Performance

Shares of LON:DOCS opened at GBX 63.10 on Thursday. The company has a market capitalization of £610.30 million, a P/E ratio of 37.12, a P/E/G ratio of 6.40 and a beta of 0.24. Dr. Martens plc has a 1-year low of GBX 53.05 and a 1-year high of GBX 100.87. The firm’s 50 day simple moving average is GBX 64.08 and its two-hundred day simple moving average is GBX 72.13. The company has a debt-to-equity ratio of 120.66, a current ratio of 2.18 and a quick ratio of 1.13.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Berenberg Bank reiterated a “buy” rating and issued a GBX 114 price target on shares of Dr. Martens in a research note on Wednesday, May 6th. Royal Bank Of Canada reiterated a “sector perform” rating on shares of Dr. Martens in a research report on Tuesday, February 3rd. Two equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, Dr. Martens presently has a consensus rating of “Moderate Buy” and an average price target of GBX 3,057.

Check Out Our Latest Research Report on DOCS

About Dr. Martens

(Get Free Report)

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.

Featured Articles

• Five stocks we like better than Dr. Martens
• Airplane Maintenance Companies That Keep Flights Moving Are Ready to Soar
• Oklo Stock Could Be Ready for Another Massive Run
• D-Wave Earnings Looked Weak, But Investors May Be Missing This
• Nebius Upside Expands as AI Feedback Loop Intensifies

Receive News & Ratings for Dr. Martens Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Martens and related companies with MarketBeat.com's FREE daily email newsletter.